{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:25:16Z","timestamp":1788348316069,"version":"build-2803163510"},"reference-count":258,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":51,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["HrZZ\u2010IP\u20102020\u201002\u20109343"],"award-info":[{"award-number":["HrZZ\u2010IP\u20102020\u201002\u20109343"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["KK.01.1.1.02.0007"],"award-info":[{"award-number":["KK.01.1.1.02.0007"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["BioMolTox"],"award-info":[{"award-number":["BioMolTox"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["iubmb.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioFactors"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\u03b2\u2010Secretase (BACE1) is the key enzyme responsible for generating amyloid\u2010\u03b2 (A\u03b2) peptides, whose aggregation and plaque formation are major hallmarks of Alzheimer's disease (AD). Owing to its central role in A\u03b2 production, BACE1 has become a widely studied therapeutic target in the search for disease\u2010modifying treatments for AD. However, evidence of numerous physiological substrates indicates that BACE1 participates in diverse biological processes, from the development and maintenance of the nervous system through control of neuronal differentiation and axonal myelination to immune response mediation by promotion of cell\u2013cell interactions. These functions prompted research into the enzyme's role in other neurodegenerative disorders such as Parkinson's disease, Niemann\u2013Pick type C disease, and Creutzfeldt\u2013Jakob disease, whose pathophysiology includes aberrant protein aggregation and\/or cognitive decline leading to dementia as seen in AD, as well as in neurological conditions such as schizophrenia and epilepsy, which are characterized by impaired neurotransmission and seizures, respectively. This review summarizes current knowledge on BACE1 substrates involved in nervous system regulation and immune response, highlights its roles at the molecular and genetic levels across aforementioned disorders, and outlines outcomes from clinical trials of BACE1 inhibitors.<\/jats:p>","DOI":"10.1002\/biof.70071","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:08:33Z","timestamp":1766398113000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["<scp>BACE1<\/scp>\n                    : Biological Functions and Involvement in the Pathophysiology of Alzheimer's Disease and Other Neurological Disorders"],"prefix":"10.1002","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1713-8915","authenticated-orcid":false,"given":"Marija","family":"Bartoli\u0107","sequence":"first","affiliation":[{"name":"Division of Toxicology Institute for Medical Research and Occupational Health  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-4994","authenticated-orcid":false,"given":"Anita","family":"Bosak","sequence":"additional","affiliation":[{"name":"Division of Toxicology Institute for Medical Research and Occupational Health  Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-378630-2.00172-9"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-378630-2.00003-7"},{"key":"e_1_2_12_4_1","unstructured":"The Human Protein Atlas: BACE1.https:\/\/www.proteinatlas.org\/ENSG00000186318\u2010BACE1\/tissue#rna_expression accessed February 21 2025."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70276-X"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1152-3"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00643"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)32449-3"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720508783954758"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/360672a0"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/990114"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5440.735"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.4.1456"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.1999.0811"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/990107"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07476.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5489.150"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi048106k"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja801269x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi200081h"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008477"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201902347R"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.173"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094568"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10758"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0993-95"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1989.tb08536.x"},{"key":"e_1_2_12_28_1","unstructured":"https:\/\/www.proteinatlas.org\/ENSG00000142192\u2010APP\/tissue accessed December 8 2023."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/341226a0"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1078\/0171-9335-00117"},{"issue":"46","key":"e_1_2_12_31_1","first-page":"1","article-title":"Amyloid\u2010\u03b2 Colocalizes With Apolipoprotein B in Absorptive Cells of the Small Intestine","volume":"8","author":"Galloway S.","year":"2009","journal-title":"Lipids in Health and Disease"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2006.07.003"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)92808-8"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000235555"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154454"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2003.02731.x"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0122"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)00555-J"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142730"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2016.00161"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0020-8"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07584.x"},{"issue":"27","key":"e_1_2_12_43_1","first-page":"1","article-title":"The Secreted APP Ectodomain sAPP\u03b1, but Not sAPP\u03b2, Protects Neurons Against A\u03b2 Oligomer\u2010Induced Dendritic Spine Loss and Increased Tau Phosphorylation","volume":"12","author":"Tackenberg C.","year":"2019","journal-title":"Molecular Brain"},{"issue":"3","key":"e_1_2_12_44_1","first-page":"1","article-title":"APP Processing in Alzheimer's Disease","volume":"4","author":"Zhang Y.\u2010W.","year":"2011","journal-title":"Molecular Brain"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11049"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2168"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.257511"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152708784936626"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0350416"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07579.x"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.200900026"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/psyg.12933"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19530-8"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4827(02)00102-7"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/378386a0"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720512799361637"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132341"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn1797"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(10)59002-1"},{"issue":"88","key":"e_1_2_12_61_1","first-page":"1","article-title":"CSF Levels of the BACE1 Substrate NRG1 Correlate With Cognition in Alzheimer's Disease","volume":"12","author":"Mouton\u2010Liger F.","year":"2020","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.30"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00302"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200113992"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00353892"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1515\/revneuro-2015-0069"},{"issue":"93","key":"e_1_2_12_67_1","first-page":"1","article-title":"The Low\u2010Density Lipoprotein Receptor\u2010Related Protein 1 and Amyloid\u2010\u03b2 Clearance in Alzheimer's Disease","volume":"6","author":"Kanekiyo T.","year":"2014","journal-title":"Frontiers in Aging Neuroscience"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414248200"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.05.017"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0006-15.2015"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021014-071846"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2011.224204"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2017_48"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414648200"},{"issue":"61","key":"e_1_2_12_75_1","first-page":"1","article-title":"Identification of BACE1 Cleavage Sites in Human Voltage\u2010Gated Sodium Channel Beta 2 Subunit","volume":"5","author":"Gersbacher M. T.","year":"2010","journal-title":"Molecular Neurodegeneration"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5446-07.2008"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2012.11.006"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.012"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700356200"},{"issue":"342","key":"e_1_2_12_81_1","first-page":"1","article-title":"Circulating Levels of IL\u20101 Family Cytokines and Receptors in Alzheimer's Disease: New Markers of Disease Progression?","volume":"15","author":"Italiani P.","year":"2018","journal-title":"Journal of Neuroinflammation"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155582"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00596-6"},{"issue":"251","key":"e_1_2_12_85_1","first-page":"1","article-title":"Pro\u2010Inflammatory Interleukin\u20106 Signaling Links Cognitive Impairments and Peripheral Metabolic Alterations in Alzheimer's Disease","volume":"11","author":"Lyra e Silva N. M.","year":"2021","journal-title":"Translational Psychiatry"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1996.tb01306.x"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00496.x"},{"issue":"174","key":"e_1_2_12_88_1","first-page":"1","article-title":"Cell Adhesion Molecule Close Homolog of L1 (CHL1) Guides the Regrowth of Regenerating Motor Axons and Regulates Synaptic Coverage of Motor Neurons","volume":"11","author":"Guseva D.","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303084200"},{"issue":"9368","key":"e_1_2_12_90_1","first-page":"1","article-title":"Homophilic Binding of the Neural Cell Adhesion Molecule CHL1 Regulates Development of Ventral Midbrain Dopaminergic Pathways","volume":"7","author":"Alsaine W. F.","year":"2017","journal-title":"Scientific Reports"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.377465"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.415505"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5620"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2009"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-243"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.37.9.658"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.047159"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2323"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.692832"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.94"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.06.005"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.579862"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23122"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2007.09.018"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhz230"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0134-z"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.12.023"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000719"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21103"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.218"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.07.017"},{"issue":"33","key":"e_1_2_12_112_1","first-page":"1","article-title":"Alzheimer Disease","volume":"7","author":"Knopman D. S.","year":"2021","journal-title":"Nature Reviews. Disease Primers"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0244-7"},{"issue":"33","key":"e_1_2_12_114_1","first-page":"1","article-title":"Alzheimer's Disease: Risk Factors and Potentially Protective Measures","volume":"26","author":"Ferreira Silva M. V.","year":"2019","journal-title":"Journal of Biomedical Science"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720506779025242"},{"key":"e_1_2_12_116_1","first-page":"896","article-title":"A Mutation in APP Protects Against Alzheimer's Disease and Age\u2010Related Cognitive Decline","volume":"48","author":"Jonsson T.","year":"2012","journal-title":"Nature"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1042\/NS20180203"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn0403-345"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-168633"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003840"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/973298"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200107030-00008"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1127-8"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.10010"},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200307010-00011"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.20087"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.1385\/JMN:25:2:127"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00315-9"},{"key":"e_1_2_12_131_1","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2022.2066750"},{"key":"e_1_2_12_132_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2020.1749447"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.116.054072"},{"key":"e_1_2_12_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14895"},{"key":"e_1_2_12_135_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126600"},{"key":"e_1_2_12_136_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009598200"},{"key":"e_1_2_12_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.02.007"},{"key":"e_1_2_12_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2010.05.006"},{"key":"e_1_2_12_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63185-9"},{"key":"e_1_2_12_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.08.016"},{"key":"e_1_2_12_141_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-151087"},{"key":"e_1_2_12_142_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200344"},{"key":"e_1_2_12_143_1","unstructured":"K. R.Patel J.Cherian K.Gohil andD.Atkinson \u201cP&T. Schizophrenia: Overview and Treatment Options \u201d39 no.9(2014):638\u2013645."},{"key":"e_1_2_12_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.67"},{"key":"e_1_2_12_145_1","first-page":"3462","article-title":"Genetics of Schizophrenia (Review)","volume":"20","author":"Trifu S. C.","year":"2020","journal-title":"Experimental and Therapeutic Medicine"},{"key":"e_1_2_12_146_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-018-0205-7"},{"key":"e_1_2_12_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.11.018"},{"key":"e_1_2_12_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2020.152176"},{"key":"e_1_2_12_149_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710373105"},{"key":"e_1_2_12_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.24"},{"key":"e_1_2_12_151_1","article-title":"Pharmacological Perspectives and Mechanisms Involved in Epileptogenesis","volume":"11","author":"Bezerra Sampaio Marques F. V.","year":"2022","journal-title":"Universal Journal of Basic and Applied Sciences"},{"key":"e_1_2_12_152_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.01023"},{"key":"e_1_2_12_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2016.11.030"},{"key":"e_1_2_12_154_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.940515"},{"key":"e_1_2_12_155_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz381"},{"key":"e_1_2_12_156_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1334-10.2010"},{"key":"e_1_2_12_157_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1602"},{"key":"e_1_2_12_158_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010222"},{"key":"e_1_2_12_159_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3458-3"},{"key":"e_1_2_12_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00488-7"},{"key":"e_1_2_12_161_1","unstructured":"https:\/\/alzheimer.ca\/sites\/default\/files\/documents\/other_dementias_cjd_e_1.pdf accessed October 29 2025."},{"key":"e_1_2_12_162_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010007"},{"key":"e_1_2_12_163_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609621104"},{"key":"e_1_2_12_164_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.278556"},{"key":"e_1_2_12_165_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059554"},{"key":"e_1_2_12_166_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000229925.52203.4c"},{"key":"e_1_2_12_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.05.019"},{"key":"e_1_2_12_168_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043926"},{"key":"e_1_2_12_169_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00097"},{"key":"e_1_2_12_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.02.008"},{"key":"e_1_2_12_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.12.163"},{"key":"e_1_2_12_172_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00011.2009"},{"key":"e_1_2_12_173_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3647-11.2011"},{"key":"e_1_2_12_174_1","unstructured":"A Safety Study of LY2811376 Single Doses in Healthy Subjects. ClinicalTrials.gov Identifier: NCT00838084. Updated July 15 2009.https:\/\/clinicaltrials.gov\/study\/NCT00838084?intr=LY2811376&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_175_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0075-0"},{"key":"e_1_2_12_176_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4129-14.2015"},{"key":"e_1_2_12_177_1","unstructured":"A Safety Study of LY2886721 Single Doses in Healthy Subjects. ClinicalTrials.gov Identifier: NCT01133405. Updated September 16 2019.https:\/\/clinicaltrials.gov\/study\/NCT01133405?term=NCT01133405&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_178_1","unstructured":"A Safety Study of LY2886721 Multiple Doses in Healthy Subjects. ClinicalTrials.gov Identifier: NCT01227252. Updated July 19 2019.https:\/\/clinicaltrials.gov\/study\/NCT01227252?term=NCT01227252&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_179_1","unstructured":"A Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT01561430. Updated May 18 2018.https:\/\/clinicaltrials.gov\/study\/NCT01561430?term=NCT01561430&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_180_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1405-14.2014"},{"key":"e_1_2_12_181_1","unstructured":"A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT01592331. Updated November 02 2016.https:\/\/clinicaltrials.gov\/study\/NCT01592331?term=NCT01592331&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_182_1","unstructured":"A Study on Safety Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT01461967 Updated November 02 2016.https:\/\/clinicaltrials.gov\/study\/NCT01461967?intr=NCT01461967&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_183_1","unstructured":"A Single\u2010Center Study of RO5508887 in Healthy Volunteers. ClinicalTrials.gov Identifier: NCT01664143. Updated November 02 2016.https:\/\/clinicaltrials.gov\/study\/NCT01664143?intr=NCT01664143&rank=1185 accessed February 17 2025."},{"key":"e_1_2_12_184_1","unstructured":"https:\/\/www.alzforum.org\/therapeutics\/rg7129 accessed February 17 2025."},{"key":"e_1_2_12_185_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00489"},{"key":"e_1_2_12_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.06.828"},{"key":"e_1_2_12_187_1","unstructured":"A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT02323334. Updated April 19 2021.https:\/\/clinicaltrials.gov\/study\/NCT02323334?intr=NCT02323334&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.06.791"},{"key":"e_1_2_12_189_1","unstructured":"A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE\u2010AD). ClinicalTrials.gov Identifier: NCT02791191. Updated April 19 2021.https:\/\/clinicaltrials.gov\/study\/NCT02791191?intr=NCT02791191&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_190_1","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-210296"},{"key":"e_1_2_12_191_1","unstructured":"A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER\u2010ALZ). ClinicalTrials.gov Identifier: NCT03367403. Updated October 13 2022.https:\/\/clinicaltrials.gov\/study\/NCT03367403?intr=NCT03367403&rank=1#study\u2010overview accessed February 17 2025."},{"key":"e_1_2_12_192_1","unstructured":"https:\/\/www.alzforum.org\/therapeutics\/ly3202626 accessed February 17 2025."},{"key":"e_1_2_12_193_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704"},{"key":"e_1_2_12_194_1","unstructured":"A Study of the Safety Tolerability and Pharmacodynamics of MK\u20108931 in Participants With Alzheimer's Disease (MK\u20108931\u2010010 AM1 (P07820 AM1)). ClinicalTrials.gov Identifier: NCT01496170. Updated October 23 2015.https:\/\/clinicaltrials.gov\/study\/NCT01496170?intr=NCT01496170&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_195_1","unstructured":"A Two\u2010Part Single\u2010Dose Study of the Pharmacokinetics of MK\u20108931 in Subjects With Renal Insufficiency (MK\u20108931\u2010009 (P08535)). ClinicalTrials.gov Identifier: NCT01537757. Updated January 26 2015.https:\/\/clinicaltrials.gov\/study\/NCT01537757?intr=NCT01537757&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_196_1","unstructured":"An Efficacy and Safety Trial of Verubecestat (MK\u20108931) in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH). ClinicalTrials.gov Identifier: NCT01739348. Updated October 24 2018.https:\/\/clinicaltrials.gov\/study\/NCT01739348?intr=NCT01739348&rank=1 accessed February 17 2025."},{"key":"e_1_2_12_197_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706441"},{"key":"e_1_2_12_198_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep21917"},{"key":"e_1_2_12_199_1","unstructured":"Efficacy and Safety Trial of Verubecestat (MK\u20108931) in Participants With Prodromal Alzheimer's Disease (MK\u20108931\u2010019) (APECS). ClinicalTrials.gov Identifier: NCT01953601. Updated May 17 2019.https:\/\/clinicaltrials.gov\/study\/NCT01953601?intr=NCT01953601&rank=1 accessed February 17 2025."},{"issue":"68","key":"e_1_2_12_200_1","first-page":"1","article-title":"Further Analyses of the Safety of Verubecestat in the Phase 3 EPOCH Trial of Mild\u2010To\u2010Moderate Alzheimer's Disease","volume":"11","author":"Egan M. F.","year":"2019","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_12_201_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812840"},{"key":"e_1_2_12_202_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01917"},{"key":"e_1_2_12_203_1","unstructured":"A Study to Investigate the Safety Tolerability and Pharmacokinetics of JNJ\u201054861911 in Healthy Volunteers Compared With Placebo. ClinicalTrials.gov Identifier: NCT01827982. Updated November 10 2014.https:\/\/clinicaltrials.gov\/study\/NCT01827982?intr=NCT01827982&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_204_1","unstructured":"A Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of JNJ\u201054861911 in Healthy Elderly Participants. ClinicalTrials.gov Identifier: NCT01887535. Updated January 14 2014.https:\/\/clinicaltrials.gov\/study\/NCT01887535?intr=NCT01887535&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.08.001"},{"key":"e_1_2_12_206_1","unstructured":"Study Investigating the Effects of JNJ\u201054861911 on Amyloid\u2010Beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer's Dementia. ClinicalTrials.gov Identifier: NCT02360657. Updated February 04 2019.https:\/\/clinicaltrials.gov\/study\/NCT02360657?intr=NCT02360657&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_207_1","unstructured":"A Study to Evaluate the Effects of JNJ\u201054861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT01978548. Updated June 25 2015.https:\/\/clinicaltrials.gov\/study\/NCT01978548?intr=NCT01978548&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_208_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0415-6"},{"key":"e_1_2_12_209_1","unstructured":"A Safety and Tolerability Study of JNJ\u201054861911 in Participants With Early Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT02260674. Updated March 03 2017.https:\/\/clinicaltrials.gov\/study\/NCT02260674?intr=NCT02260674&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_210_1","unstructured":"An Extension Study to Evaluate the Long\u2010Term Safety and Solerability of JNJ\u201054861911 in Participants in the Early Alzheimer's Disease Spectrum. ClinicalTrials.gov Identifier: NCT02406027. Updated February 12 2025.https:\/\/clinicaltrials.gov\/study\/NCT02406027?intr=NCT02406027&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_211_1","unstructured":"An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY). ClinicalTrials.gov Identifier: NCT02569398. Updated February 12 2025.https:\/\/clinicaltrials.gov\/study\/NCT02569398?intr=NCT02569398&rank=1 accessed February 18 2025."},{"issue":"58","key":"e_1_2_12_212_1","first-page":"1","article-title":"Long\u2010Term Safety and Tolerability of Atabecestat (JNJ\u201054861911), an Oral BACE1 Inhibitor, in Early Alzheimer's Disease Spectrum Patients: A Randomized, Double\u2010Blind, Placebo\u2010Controlled Study and a Two\u2010Period Extension Study","volume":"12","author":"Novak G.","year":"2020","journal-title":"Alzheimer's Research & Therapy"},{"key":"e_1_2_12_213_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.11.004"},{"key":"e_1_2_12_214_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150834"},{"key":"e_1_2_12_215_1","unstructured":"A Single Dose Study to Assess the Safety Effects and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects. ClinicalTrials.gov Identifier: NCT01739647. Updated August 27 2013.https:\/\/clinicaltrials.gov\/study\/NCT01739647?intr=NCT01739647&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_216_1","unstructured":"A Two\u2010Part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients. ClinicalTrials.gov Identifier: NCT01795339. Updated April 03 2014.https:\/\/clinicaltrials.gov\/study\/NCT01795339?intr=NCT01795339&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_217_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160701"},{"key":"e_1_2_12_218_1","unstructured":"An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH). ClinicalTrials.gov Identifier: NCT02245737. Updated December 03 2019.https:\/\/clinicaltrials.gov\/study\/NCT02245737?intr=NCT02245737&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_219_1","unstructured":"A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK\u2010ALZ). ClinicalTrials.gov Identifier: NCT02783573. Updated December 03 2019.https:\/\/clinicaltrials.gov\/study\/NCT02783573?intr=NCT02783573&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_220_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3988"},{"key":"e_1_2_12_221_1","unstructured":"https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/bace\u2010inhibitors\u2010postmortem\u2010one\u2010live\u2010updates\u2010two accessed February 18 2025."},{"issue":"7","key":"e_1_2_12_222_1","first-page":"P841","article-title":"P4\u2010163: A Single Dose of the Beta\u2010Secretase Inhibitor, e2609, Decreases CSF bace1 Enzymatic Activity in Cynomolgus Monkeys","volume":"11","author":"Matijevic M.","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"7","key":"e_1_2_12_223_1","first-page":"P944","article-title":"P3\u2010037: Preclinical Studies With Elenbecestat, a Novel bace1 Inhibitor, Show no Evidence of Hypopigmentation","volume":"13","author":"Moriyama T.","year":"2017","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_224_1","unstructured":"Evaluation of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort. ClinicalTrials.gov Identifier: NCT01294540. Updated August 29 2013.https:\/\/clinicaltrials.gov\/study\/NCT01294540?intr=NCT01294540&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_225_1","unstructured":"https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/wave\u2010new\u2010bace\u2010inhibitors\u2010heading\u2010phase\u20102 accessed February 18 2025."},{"key":"e_1_2_12_226_1","unstructured":"Evaluation of the Safety Pharmacokinetics and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects. ClinicalTrials.gov Identifier: NCT01511783. Updated November 03 2015.https:\/\/clinicaltrials.gov\/study\/NCT01511783 accessed February 18 2025."},{"key":"e_1_2_12_227_1","unstructured":"Dose\u2010Finding Study to Evaluate Safety Tolerability and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT02322021. Updated March 05 2021.https:\/\/clinicaltrials.gov\/study\/NCT02322021?intr=NCT02322021&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_228_1","unstructured":"https:\/\/investors.biogen.com\/news\u2010releases\/news\u2010release\u2010details\/phase\u2010ii\u2010clinical\u2010study\u2010elenbecestat\u2010demonstrates\u2010safety\u2010and accessed February 18 2025."},{"key":"e_1_2_12_229_1","unstructured":"A 24\u2010Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1). ClinicalTrials.gov Identifier: NCT02956486. Updated February 03 2021.https:\/\/clinicaltrials.gov\/study\/NCT02956486?intr=Elenbecestat&aggFilters=phase:3&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_230_1","unstructured":"https:\/\/www.alzforum.org\/news\/research\u2010news\/end\u2010bace\u2010inhibitors\u2010elenbecestat\u2010trials\u2010halted\u2010amid\u2010safety\u2010concerns accessed February 18 2025."},{"key":"e_1_2_12_231_1","unstructured":"International Conference on Alzheimer's and Parkinson's Diseases 2021 (Virtual): Drop of Hope? No Cognitive Worsening on BACE Inhibitor.https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/drop\u2010hope\u2010no\u2010cognitive\u2010worsening\u2010bace\u2010inhibitor accessed February 18 2025."},{"key":"e_1_2_12_232_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809316"},{"key":"e_1_2_12_233_1","unstructured":"Dose\u2010Ranging Safety and Tolerability Study in Subjects \u226560\u2009Years of Age. ClinicalTrials.gov Identifier: NCT02576639. Updated August 11 2017.https:\/\/clinicaltrials.gov\/study\/NCT02576639?intr=NCT02576639&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_234_1","unstructured":"A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS2). ClinicalTrials.gov Identifier: NCT03131453. Updated August 05 2021.https:\/\/clinicaltrials.gov\/study\/NCT03131453?intr=NCT03131453&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_235_1","unstructured":"A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GS1). ClinicalTrials.gov Identifier: NCT02565511. Updated July 08 2021.https:\/\/clinicaltrials.gov\/study\/NCT02565511?intr=NCT02565511&rank=1 accessed February 18 2025."},{"key":"e_1_2_12_236_1","unstructured":"Alzheimer's Association International Conference 2020 (Virtual Meeting Only): Umibecestat\u2010Driven Cognitive Decline Is Reversible.https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/umibecestat\u2010driven\u2010cognitive\u2010decline\u2010reversible accessed February 19 2025."},{"key":"e_1_2_12_237_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00246"},{"key":"e_1_2_12_238_1","unstructured":"First\u2010in\u2010Human Study of Single and Multiple Ascending Doses of PF\u201006751979. ClinicalTrials.gov Identifier: NCT02509117. Updated November 01 2018.https:\/\/clinicaltrials.gov\/study\/NCT02509117?intr=NCT02509117&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_239_1","unstructured":"Clinical Trial in Healthy Volunteers and Health Elderly Volunteers to Evaluate the Safety Tolerability and Blood Concentration After Single and Multiple Escalating Oral Doses of PF\u201006751979. ClinicalTrials.gov Identifier: NCT02793232. Updated September 17 2018.https:\/\/clinicaltrials.gov\/study\/NCT02793232?intr=NCT02793232&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_240_1","unstructured":"The Study is to Evaluate the Effect of Multiple Doses PF\u201006751979 on the Pharmacokinetics of Midazolam in Healthy Adults. ClinicalTrials.gov Identifier: NCT03126721. Updated September 17 2018.https:\/\/clinicaltrials.gov\/study\/NCT03126721?intr=NCT03126721&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_241_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190228"},{"key":"e_1_2_12_242_1","unstructured":"ALZFORUM: PF\u201006751979.https:\/\/www.alzforum.org\/therapeutics\/pf\u201006751979 accessed February 19 2025."},{"key":"e_1_2_12_243_1","unstructured":"Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male\/Female Volunteers. ClinicalTrials.gov Identifier: NCT02254161. Updated August 31 2018.https:\/\/clinicaltrials.gov\/study\/NCT02254161?intr=NCT02254161&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_244_1","unstructured":"Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers. ClinicalTrials.gov Identifier: NCT02106247. Updated July 10 2014.https:\/\/clinicaltrials.gov\/study\/NCT02106247?intr=NCT02106247&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_245_1","unstructured":"Safety Tolerability Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers Including Investigation of the Effect of Food on the Bioavailability of BI 1181181. ClinicalTrials.gov Identifier: NCT02044406. Updated October 08 2014.https:\/\/clinicaltrials.gov\/study\/NCT02044406?intr=NCT02044406&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_246_1","unstructured":"ALZFORUM: BI 1181181.https:\/\/www.alzforum.org\/therapeutics\/bi\u20101181181 accessed February 19 2025."},{"issue":"7","key":"e_1_2_12_247_1","first-page":"P477","article-title":"P1\u2010314: Pharmacological Characterization of the New bace1 Inhibitor Bi 1181181","volume":"11","author":"Dorner\u2010Ciossek C.","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"7","key":"e_1_2_12_248_1","first-page":"P740","article-title":"P3\u2010282: Single Oral Doses of the Novel Bace Inhibitor Bi 1181181 Significantly Reduce Concentrations of Cerebrospinal Fluid Amyloid\u2010Beta Peptides in Healthy Subjects","volume":"11","author":"Borta A.","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"7","key":"e_1_2_12_249_1","first-page":"P740","article-title":"P3\u2010283: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Bace Inhibitor bi1181181 After Oral Administration of Single Ascending Doses in Healthy Subjects","volume":"11","author":"Nicolas L.","year":"2015","journal-title":"Alzheimer's & Dementia"},{"key":"e_1_2_12_250_1","unstructured":"ALZFORUM: BACE Inhibitor Trial Put on Hold.https:\/\/www.alzforum.org\/news\/research\u2010news\/bace\u2010inhibitor\u2010trial\u2010put\u2010hold accessed February 19 2025."},{"key":"e_1_2_12_251_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711413165"},{"key":"e_1_2_12_252_1","unstructured":"Thalidomide for Patients With Mild to Moderate Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT01094340. Updated August 08 2012.https:\/\/clinicaltrials.gov\/study\/NCT01094340?intr=NCT01094340&rank=1 accessed February 19 2025."},{"key":"e_1_2_12_253_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-99"},{"key":"e_1_2_12_254_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055091"},{"key":"e_1_2_12_255_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205014666170117141330"},{"key":"e_1_2_12_256_1","unstructured":"MCLENA\u20101: A clinical trial for the assessment of lenalidomide in amnestic MCI patients (MCLENA\u20101). ClinicalTrials.gov Identifier: NCT04032626. Updated June 13 2025.https:\/\/clinicaltrials.gov\/study\/NCT04032626?intr=NCT04032626&rank=1 accessed October 29 2025."},{"key":"e_1_2_12_257_1","unstructured":"MCLENA\u20102: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT06177028. Updated May 18 2025.https:\/\/clinicaltrials.gov\/study\/NCT06177028?intr=NCT06177028&rank=1 accessed October 29 2025."},{"key":"e_1_2_12_258_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00545-1"},{"key":"e_1_2_12_259_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24969"}],"container-title":["BioFactors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/biof.70071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/biof.70071","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/biof.70071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:12:51Z","timestamp":1778775171000},"score":1,"resource":{"primary":{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/10.1002\/biof.70071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":258,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/biof.70071"],"URL":"https:\/\/doi.org\/10.1002\/biof.70071","archive":["Portico"],"relation":{},"ISSN":["0951-6433","1872-8081"],"issn-type":[{"value":"0951-6433","type":"print"},{"value":"1872-8081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70071"}}